Do multivitamins help with healthy ageing?
For cognition, multivitamins have the strongest support in older adults. For a longer life or a healthier heart there is no convincing evidence, and caution is warranted for those with a predisposition to macular degeneration.
For cognition, the evidence is strongest. Multiple randomised trials show that multivitamins improve memory and general cognition in older adults1. This is one of the more consistent findings in this field of research.
For cancer risk, there is a cautiously positive signal. A meta-analysis of three large trials, including COSMOS and PHS2, found a small but statistically significant risk reduction, but the effect was visible in men and not in women2. Keep that nuance in mind.
On cardiovascular health and mortality, a multivitamin does little to nothing. A six-month study tested a combination of ten popular supplements plus a multivitamin in healthy adults. There was no effect whatsoever on blood pressure, blood lipids, blood sugar or inflammatory markers3. Both randomised and observational studies confirm that multivitamins do not reduce overall mortality1.
There is one safety signal that deserves serious attention: a meta-analysis linked multivitamin supplementation to a higher risk of faster progression of macular degeneration, an eye condition1. If you have a predisposition to that condition, this is a relevant factor in the decision.
Finally: standard multivitamins usually contain too little vitamin D to achieve adequate levels in older adults in nursing homes; doses below 20 micrograms per day are insufficient for that purpose4. And only around 11% of 2,877 Chinese centenarians studied used any supplements at all5, although this says nothing about cause and effect. Guidelines acknowledge that a multivitamin can be a practical way to fill nutritional gaps in people with a modest diet, but food always remains the first choice6.
The claims are based on multiple randomised trials and a meta-analysis of three large randomised trials (PMID 37561385, 41308839), supplemented by observational and laboratory research. The strength of evidence differs by outcome: moderate for cognition and cancer risk, limited for telomeres and mechanisms. All claims are derived from the PMID sources provided.